drugset / Trial / NCT07159243
Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain
Phase 2
Not yet recruiting
180 enrolled
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multi-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and PK parameter of HL-1186 tablet for diabetic peripheral neuropathic pain.
Timeline
- Start
- 2025-09
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HL-1186 | Unknown | — | Oral |